Shanghai Runda Medical Technology Co., Ltd. (SHA:603108)
China · Delayed Price · Currency is CNY 13.63
-0.07 (-0.51%)
May 19, 2026, 10:25 AM CST
SHA:603108 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 6,847 | 6,999 | 8,306 | 9,140 | 10,487 | 8,853 |
Other Revenue | - | - | 5.85 | 7.15 | 7.13 | 6.83 |
| 6,847 | 6,999 | 8,312 | 9,147 | 10,494 | 8,860 | |
Revenue Growth (YoY) | -13.34% | -15.80% | -9.13% | -12.84% | 18.45% | 25.34% |
Cost of Revenue | 5,345 | 5,502 | 6,211 | 6,731 | 7,564 | 6,468 |
Gross Profit | 1,503 | 1,497 | 2,101 | 2,416 | 2,931 | 2,392 |
Selling, General & Admin | 1,154 | 1,187 | 1,321 | 1,423 | 1,578 | 1,244 |
Research & Development | 108.19 | 108.01 | 116.16 | 147.14 | 146.22 | 122.71 |
Other Operating Expenses | 2.55 | -2.85 | 40.98 | 47.05 | 29.76 | 24.66 |
Operating Expenses | 1,265 | 1,292 | 1,545 | 1,702 | 1,952 | 1,443 |
Operating Income | 237.5 | 204.62 | 556.14 | 713.53 | 978.14 | 949.16 |
Interest Expense | - | - | -312.86 | -334.04 | -317.92 | -281.92 |
Interest & Investment Income | 12.6 | 20.79 | 123.19 | 254.94 | 145.28 | 142.18 |
Currency Exchange Gain (Loss) | - | - | -5.97 | 3.18 | -1.65 | -4.73 |
Other Non Operating Income (Expenses) | -490.1 | -480.43 | -22.43 | -12.15 | 6.8 | -27.55 |
EBT Excluding Unusual Items | -240 | -255.02 | 338.06 | 625.46 | 810.65 | 777.14 |
Impairment of Goodwill | - | - | -29.13 | -10.41 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -7.15 |
Gain (Loss) on Sale of Assets | 0.99 | 3.12 | 6.48 | 8.73 | 2.67 | -1.52 |
Asset Writedown | -208.93 | -208.74 | - | -11.07 | -34.71 | - |
Other Unusual Items | - | - | 30.12 | 42.85 | 41.05 | 11.99 |
Pretax Income | -447.94 | -460.64 | 345.54 | 655.56 | 819.65 | 780.46 |
Income Tax Expense | 48.32 | 57.51 | 156.08 | 212.92 | 164.54 | 182.26 |
Earnings From Continuing Operations | -496.26 | -518.15 | 189.46 | 442.64 | 655.11 | 598.2 |
Minority Interest in Earnings | -36.43 | -30.24 | -134.18 | -169.34 | -237.36 | -217.97 |
Net Income | -532.7 | -548.39 | 55.28 | 273.3 | 417.75 | 380.23 |
Net Income to Common | -532.7 | -548.39 | 55.28 | 273.3 | 417.75 | 380.23 |
Net Income Growth | - | - | -79.77% | -34.58% | 9.87% | 15.23% |
Shares Outstanding (Basic) | 594 | 603 | 614 | 581 | 580 | 576 |
Shares Outstanding (Diluted) | 594 | 603 | 614 | 581 | 597 | 594 |
Shares Change (YoY) | -5.77% | -1.89% | 5.63% | -2.56% | 0.45% | 2.63% |
EPS (Basic) | -0.90 | -0.91 | 0.09 | 0.47 | 0.72 | 0.66 |
EPS (Diluted) | -0.90 | -0.91 | 0.09 | 0.47 | 0.70 | 0.64 |
EPS Growth | - | - | -80.85% | -32.86% | 9.38% | 12.28% |
Free Cash Flow | 297.9 | 386.74 | 417.78 | 409.84 | -700.98 | 70.03 |
Free Cash Flow Per Share | 0.50 | 0.64 | 0.68 | 0.70 | -1.18 | 0.12 |
Dividend Per Share | - | - | 0.030 | 0.100 | 0.150 | - |
Dividend Growth | - | - | -70.00% | -33.33% | - | - |
Gross Margin | 21.95% | 21.39% | 25.28% | 26.41% | 27.93% | 27.00% |
Operating Margin | 3.47% | 2.92% | 6.69% | 7.80% | 9.32% | 10.71% |
Profit Margin | -7.78% | -7.84% | 0.66% | 2.99% | 3.98% | 4.29% |
Free Cash Flow Margin | 4.35% | 5.53% | 5.03% | 4.48% | -6.68% | 0.79% |
EBITDA | 543.75 | 512.97 | 872.9 | 1,031 | 1,286 | 1,240 |
EBITDA Margin | 7.94% | 7.33% | 10.50% | 11.27% | 12.25% | 14.00% |
D&A For EBITDA | 306.25 | 308.35 | 316.76 | 317.48 | 307.71 | 291.06 |
EBIT | 237.5 | 204.62 | 556.14 | 713.53 | 978.14 | 949.16 |
EBIT Margin | 3.47% | 2.92% | 6.69% | 7.80% | 9.32% | 10.71% |
Effective Tax Rate | - | - | 45.17% | 32.48% | 20.08% | 23.35% |
Revenue as Reported | - | - | 8,312 | 9,147 | 10,494 | 8,860 |
Advertising Expenses | - | - | 17.3 | 21.28 | 49.57 | 58.12 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.